Skip to main content
ARVINAS, INC. logo

ARVINAS, INC. — Investor Relations & Filings

Ticker · ARVN ISIN · US04335A1051 US Professional, scientific and technical activities
Filings indexed 549 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country US United States of America
Listing US ARVN

About ARVINAS, INC.

https://www.arvinas.com/

Arvinas, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics based on targeted protein degradation. The company is a leader in this field, utilizing its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform to create a new class of drugs. This technology is designed to harness the body's own cellular machinery to selectively remove disease-causing proteins. Arvinas is advancing a pipeline of investigational therapies targeting debilitating and life-threatening diseases, with a primary focus on oncology and neuroscience. The company was the first in its field to advance an investigational drug through a pivotal trial and submit a New Drug Application to U.S. regulators.

Recent filings

Filing Released Lang Actions
8-K - ARVINAS, INC. (0001655759) (Filer)
Regulatory Filings
2026-05-12 English
8-K - ARVINAS, INC. (0001655759) (Filer)
Regulatory Filings
2026-05-12 English
10-Q - ARVINAS, INC. (0001655759) (Filer)
Interim / Quarterly Report
2026-05-11 English
8-K - ARVINAS, INC. (0001655759) (Filer)
Regulatory Filings
2026-05-01 English
ARS - ARVINAS, INC. (0001655759) (Filer)
Annual Report
2026-04-29 English
DEF 14A - ARVINAS, INC. (0001655759) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.